5-Arylaminouracil Derivatives: New Inhibitors of Mycobacterium tuberculosis

Chem Biol Drug Des. 2015 Dec;86(6):1387-96. doi: 10.1111/cbdd.12603. Epub 2015 Jul 14.

Abstract

Three series of 5-arylaminouracil derivatives, including 5-(phenylamino)uracils, 1-(4'-hydroxy-2'-cyclopenten-1'-yl)-5-(phenylamino)uracils, and 1,3-di-(4'-hydroxy-2'-cyclopenten-1'-yl)-5-(phenylamino)uracils, were synthesized and screened for potential antimicrobial activity. Most of compounds had a negative effect on the growth of the Mycobacterium tuberculosis H37Rv strain, with 100% inhibition observed at concentrations between 5 and 40 μg/mL. Of those, 1-(4'-hydroxy-2'-cyclopenten-1'-yl)-3-(4‴-hydroxy-2‴-cyclopenten-1‴-yl)-5-(4″-butyloxyphenylamino)uracil proved to be the most active among tested compounds against the M. tuberculosis multidrug-resistant strain MS-115 (MIC90 5 μg/mL). In addition, the thymidylate kinase of M. tuberculosis was evaluated as a possible enzymatic target.

Keywords: Mycobacterium tuberculosis; carbocyclic nucleosides; uracil derivatives.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antitubercular Agents / chemical synthesis
  • Antitubercular Agents / chemistry*
  • Antitubercular Agents / pharmacology*
  • Cell Line, Tumor
  • Chlorocebus aethiops
  • Drug Design
  • Enzyme Inhibitors / chemical synthesis
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / pharmacology
  • Humans
  • Microbial Sensitivity Tests
  • Mycobacterium tuberculosis / drug effects*
  • Mycobacterium tuberculosis / enzymology
  • Mycobacterium tuberculosis / growth & development
  • Nucleoside-Phosphate Kinase / antagonists & inhibitors
  • Structure-Activity Relationship
  • Tuberculosis / drug therapy
  • Uracil / analogs & derivatives*
  • Uracil / chemistry
  • Uracil / pharmacology
  • Vero Cells

Substances

  • Antitubercular Agents
  • Enzyme Inhibitors
  • Uracil
  • Nucleoside-Phosphate Kinase
  • dTMP kinase